Projektbeschreibung
Kardiovaskuläre Gesundheit älterer Menschen durch Polypillen-Einnahme verbessern
Die Behandlung von Herz-Kreislauf-Erkrankungen erfordert häufig eine Kombination von Medikamenten, wodurch die Therapietreue oft suboptimal ausfällt. Dies verringert die Wirksamkeit und den klinischen Nutzen, verschlimmert die Krankheitssymptome und erhöht die Sterblichkeit. Das Ziel des EU-finanzierten Projekts SECURE lautet, eine fest dosierte Kombinations-Polypille zur kardiovaskulären Sekundärprävention bei Personen ab 65 Jahren zu bewerten. Im Rahmen einer klinischen Studie soll der potenzielle Nutzen der Polypille als eine kosteneffiziente und weltweit zugängliche Behandlungsstrategie im Vergleich zur Standardtherapie bewertet werden. Zu den sekundären Wirksamkeitsendpunkten zählen die Bewertung der Therapietreue, die Kontrolle von Risikofaktoren, die pharmakoökonomischen Auswirkungen, regionale Unterschiede und die Bereitstellung von Informationen für klinische Leitlinien und Empfehlungen.
Ziel
While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population (≥ 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.
Wissenschaftliches Gebiet
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencesbiological sciencesbiochemistrybiomoleculeslipids
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesbasic medicineneurologystroke
- social sciencespolitical sciencesgovernment systems
Schlüsselbegriffe
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-PHC-2014-two-stage
Finanzierungsplan
RIA - Research and Innovation actionKoordinator
28029 Madrid
Spanien